Lung Cancer: Assessing Maintenance and Early Second-Line Therapies
CME Monograph - August 2009
Non-small cell lung cancer has long been treated with first-line platinum-based chemotherapy for 4 to 6 cycles followed by a break, then second-line treatment upon progression. This CME activity presents new data and discussion of 3 case studies addressing two new approaches that challenge the current paradigm: (1) early second-line chemotherapy and (2) adding targeted antibodies to the chemotherapy followed by a maintenance antibody phase of treatment. Physicians need to be aware of these data and their implications for practice change, and be able to assess the use of early second-line treatment or combination plus maintenance therapy for individual patients.
Program Faculty
Thomas J. Lynch, Jr., MD
Director, Yale Cancer Center, Physician-in-Chief
Smilow Cancer Center at Yale - New Haven, Connecticut
Alan B. Sandler, MD
Division Chief, Hematology/Oncology
Oregon Health and Science University, Portland, Oregon
Panos Fidias, MD
Clinical Director, Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Nasser H. Hanna, MD
Division of Hematology/Oncology,Indiana University
School of Medicine, Indianapolis, Indiana
Shadia Jalal, MD
Division of Hematology/Oncology Indiana University
School of Medicine, Indianapolis, Indiana
Educational Objectives
- Discuss the rationale for early second-line treatment of non–small cell lung cancer (NSCLC).
- Discuss advantages and disadvantages of maintenance antibody therapy in NSCLC.
- Assess treatment strategies incorporating early second-line and/ or maintenance protocols for individual patients.
- Assess implications of data on early second-line and maintenance protocols for practice change.
Educational Grant Support
The program is supported by educational grants provided by: Genentech BioOncology and OSI Oncology, and sanofi-aventis, U.S.
Sponsorship
CME sponsorship and program management were provided by InforMEDical.
The CME activity has expired.
